CC-671 is a potent and selective dual inhibitor of TTK (Mps1) and CLK2.

6-Dimethylaminopurine is a novel and potent serine threonine protein kinase inhibitor which inhibits the germinal vesicle breakdown and the meiotic maturation of oocytes.

CKI-7 2HCl is a novel, potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM.

CVT-313 is a novel and potent inhibitor of CDK2.

Atuveciclib (formerly known as BAY-1143572) is novel, potent, oral and highly selective PTEFb/CDK9 inhibitor with antitumor activity. It inhibits CDK9/CycT1 with an IC50 of 13 nM and is more than 100-fold more selective for CDK9 over CDK2. It also inhibits GSK3 kinase with IC50 values of 45 nM and 87 nM for GSK3α and GSK3β […]

AT7519 trifluoroacetate is an orally bioavailable small molecule, potent and multi-CDK (cyclin-dependent kinase) inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM.

XL413 HCl (XL-413; BMS863233; XL 413; BMS-863233), the hydrochloride salt of XL413, is a novel and selective cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antitumor activity.

(±)-BAY-1251152 is a racemic mixture of BAY-1251152 which is a novel, potent and highly selective PTEF/CDK9 inhibitor.

Atuveciclib S-enantiomer (formerly known as BAY-1143572), the S-isomer of Atuveciclib, is novel, potent, orally bioactive and highly selective PTEFb/CDK9 inhibitor. It inhibits CDK9/CycT1 with an IC50 of 16 nM and is more than 100-fold more selective for CDK9 over CDK2. It also inhibits GSK3 kinase with IC50 values of 45 nM and 87 nM for […]

THZ2, a THZ1 analog, is a novel, potent and selective CDK7 inhibitor with an IC50 of 13.9 nM. THZ2 has the potential for treating triple-negative breast cancer (TNBC) and is able to overcome the instability issue of THZ1 in vivo.